当前位置: 首页 >> 检索结果
941. Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?
作者: Hans Dieter Nischalke.;Christina Nischalke.;Franziska Schmalz.;Christine Möller.;Benjamin Krämer.;Alexandra Funken.;Adrian Goldspink.;Jacob Nattermann.;Christian Strassburg.;Philipp Lutz.
来源: Gut. 2024年73卷7期1219-1222页 942. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).
作者: Ángeles Pérez-Aisa.;Olga P Nyssen.;Alma Keco-Huerga.;Luís Rodrigo.;Alfredo J Lucendo.;Blas J Gomez-Rodriguez.;Juan Ortuño.;Mónica Perona.;José María Huguet.;Oscar Núñez.;Luis Fernandez-Salazar.;Jesus Barrio.;Angel Lanas.;Eduardo Iyo.;Pilar Mata Romero.;Miguel Fernández-Bermejo.;Barbara Gomez.;Ana Garre.;Judith Gomez-Camarero.;Luis Javier Lamuela.;Ana Campillo.;Luisa de la Peña-Negro.;Manuel Dominguez Cajal.;Luis Bujanda.;Diego Burgos-Santamaría.;Fernando Bermejo.;Víctor González-Carrera.;Ramón Pajares.;Pedro Almela Notari.;Javier Tejedor-Tejada.;Montserrat Planella.;Itxaso Jiménez.;Yolanda Arguedas Lázaro.;Antonio Cuadrado-Lavín.;Isabel Pérez-Martínez.;Edurne Amorena.;Jesús M Gonzalez-Santiago.;Teresa Angueira.;Virginia Flores.;Samuel J Martínez-Domínguez.;Manuel Pabón-Carrasco.;Benito Velayos.;Alicia Algaba.;Consuelo Ramírez.;Enrique Alfaro Almajano.;Manuel Castro-Fernandez.;Noelia Alcaide.;Patricia Sanz Segura.;Anna Cano-Català.;Natalia García-Morales.;Leticia Moreira.;Francis Mégraud.;Colm O'Morain.;Xavier Calvet.;Javier P Gisbert.
来源: Gut. 2023年72卷11期2031-2038页
The recommended schedule for single capsule bismuth quadruple therapy (scBQT, Pylera) includes a proton pump inhibitor (PPI) two times a day and three scBQT capsules four times a day. Four times a day treatments are inconvenient and reduce adherence. In contrast, adherence improves with three times a day schedules. In clinical practice, many gastroenterologists use four capsule scBQT three times a day. However, the effectiveness and safety of this latter approach remain uncertain.
943. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.
作者: Robert S Bresalier.;Carlo Senore.;Graeme P Young.;James Allison.;Robert Benamouzig.;Sally Benton.;Patrick M M Bossuyt.;Luis Caro.;Beatriz Carvalho.;Han-Mo Chiu.;Veerle M H Coupé.;Willemijn de Klaver.;Clasine Maria de Klerk.;Evelien Dekker.;Sunil Dolwani.;Callum G Fraser.;William Grady.;Lydia Guittet.;Samir Gupta.;Stephen P Halloran.;Ulrike Haug.;Geir Hoff.;Steven Itzkowitz.;Tim Kortlever.;Anastasios Koulaouzidis.;Uri Ladabaum.;Beatrice Lauby-Secretan.;Mārcis Leja.;Bernard Levin.;Theodore Robert Levin.;Finlay Macrae.;Gerrit A Meijer.;Joshua Melson.;Colm O'Morain.;Susan Parry.;Linda Rabeneck.;David F Ransohoff.;Roque Sáenz.;Hiroshi Saito.;Silvia Sanduleanu-Dascalescu.;Robert E Schoen.;Kevin Selby.;Harminder Singh.;Robert J C Steele.;Joseph J Y Sung.;Erin Leigh Symonds.;Sidney J Winawer.; .
来源: Gut. 2023年72卷10期1904-1918页
New screening tests for colorectal cancer (CRC) are rapidly emerging. Conducting trials with mortality reduction as the end point supporting their adoption is challenging. We re-examined the principles underlying evaluation of new non-invasive tests in view of technological developments and identification of new biomarkers.
944. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.
作者: Zhiyuan Xu.;Yida Huang.;Can Hu.;Lingbin Du.;Yi-An Du.;Yanqiang Zhang.;Jiangjiang Qin.;Wanshan Liu.;Ruimin Wang.;Shouzhi Yang.;Jiao Wu.;Jing Cao.;Juxiang Zhang.;Gui-Ping Chen.;Hang Lv.;Ping Zhao.;Weiyang He.;Xiaoliang Wang.;Min Xu.;Pingfang Wang.;Chuanshen Hong.;Li-Tao Yang.;Jingli Xu.;Jiahui Chen.;Qing Wei.;Ruolan Zhang.;Li Yuan.;Kun Qian.;Xiangdong Cheng.
来源: Gut. 2023年72卷11期2051-2067页
Metabolic biomarkers are expected to decode the phenotype of gastric cancer (GC) and lead to high-performance blood tests towards GC diagnosis and prognosis. We attempted to develop diagnostic and prognostic models for GC based on plasma metabolic information.
945. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
作者: Evan S Dellon.;Kathryn A Peterson.;Benjamin L Mitlyng.;Alina Iuga.;Christine E Bookhout.;Lindsay M Cortright.;Kacie B Walker.;Timothy S Gee.;Sarah J McGee.;Brenderia A Cameron.;Joseph A Galanko.;John T Woosley.;Swathi Eluri.;Susan E Moist.;Ikuo Hirano.
来源: Gut. 2023年72卷10期1828-1837页
We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE).
946. Treatment of adenoma recurrence after endoscopic mucosal resection.
作者: David J Tate.;Lobke Desomer.;Maria Eva Argenziano.;Neha Mahajan.;Mayenaaz Sidhu.;Sergei Vosko.;Neal Shahidi.;Eric Lee.;Stephen J Williams.;Nicholas G Burgess.;Michael J Bourke.
来源: Gut. 2023年72卷10期1875-1886页
Residual or recurrent adenoma (RRA) after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (LNPCPs) of ≥20 mm is a major limitation. Data on outcomes of the endoscopic treatment of recurrence are scarce, and no evidence-based standard exists. We investigated the efficacy of endoscopic retreatment over time in a large prospective cohort.
948. Microbiome variance of the small bowel in Crohn's disease.
作者: Lucas Wauters.;Raul Y Tito.;Matthias Ceulemans.;An Outtier.;Leen Rymenans.;Chloë Verspecht.;João Sabino.;Marc Ferrante.;Séverine Vermeire.;Tim Vanuytsel.;Jeroen Raes.
来源: Gut. 2023年72卷8期1626-1628页 949. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.
作者: Long Long Cao.;Heng Lu.;Mohammed Soutto.;Nadeem Bhat.;Zheng Chen.;Dunfa Peng.;Ahmed Gomaa.;Jia Bin Wang.;Jian Wei Xie.;Ping Li.;Chao Hui Zheng.;Sachiyo Nomura.;Jashodeep Datta.;Nipun Merchant.;Zhi Bin Chen.;Alejandro Villarino.;Alexander Zaika.;Chang Ming Huang.;Wael El-Rifai.
来源: Gut. 2023年72卷11期2038-2050页
Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option.
950. Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
作者: Alessia Potenza.;Chiara Balestrieri.;Martina Spiga.;Luca Albarello.;Federica Pedica.;Francesco Manfredi.;Beatrice Claudia Cianciotti.;Claudia De Lalla.;Oronza A Botrugno.;Cristina Faccani.;Lorena Stasi.;Elena Tassi.;Silvia Bonfiglio.;Giulia Maria Scotti.;Miriam Redegalli.;Donatella Biancolini.;Barbara Camisa.;Elena Tiziano.;Camilla Sirini.;Monica Casucci.;Chiara Iozzi.;Danilo Abbati.;Fabio Simeoni.;Dejan Lazarevic.;Ugo Elmore.;Guido Fiorentini.;Giulia Di Lullo.;Giulia Casorati.;Claudio Doglioni.;Giovanni Tonon.;Paolo Dellabona.;Riccardo Rosati.;Luca Aldrighetti.;Eliana Ruggiero.;Chiara Bonini.
来源: Gut. 2023年72卷10期1887-1903页
Colorectal tumours are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumour progression but are burdened by immunosuppressive signals, which might vary from primary to metastatic stages. Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases, and genome editing tools to develop CRC-specific engineered T cells.
951. Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
作者: Nanne K H de Boer.;Melek Simsek.;Berrie Meijer.;Markus F Neurath.;Ad van Bodegraven.;Chris J J Mulder.
来源: Gut. 2023年72卷10期1985-1991页
Drug rediscovery refers to the principle of using 'old' drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.
952. Clarithromycin-containing triple therapy for Helicobacter pylori eradication is inducing increased long-term resistant bacteria communities in the gut.
作者: Olga Sjomina.;Reinis Vangravs.;Elīna Ļeonova.;Inese Poļaka.;Dārta Pūpola.;Kristaps Čivkulis.;Aleksandra Jeniceka.;Sergejs Paršutins.;Ilmārs Stonāns.;Jin Young Park.;Lars Engstrand.;Mārcis Leja.
来源: Gut. 2024年73卷7期1214-1215页 954. Persistent villous atrophy predicts development of complications and mortality in adult patients with coeliac disease: a multicentre longitudinal cohort study and development of a score to identify high-risk patients.
作者: Annalisa Schiepatti.;Stiliano Maimaris.;Suneil A Raju.;Olivia L Green.;Giulia Mantica.;Amelie Therrien.;David Flores-Marin.;Justin Linden.;Fernando Fernández-Bañares.;Maria Esteve.;Daniel Leffler.;Federico Biagi.;David S Sanders.
来源: Gut. 2023年72卷11期2095-2102页
Persistent villous atrophy (pVA) in coeliac disease (CD) despite a gluten-free diet (GFD) has unclear meaning. We aimed to (i) study the relationship between pVA and long-term outcomes and (ii) develop a score to identify patients at risk of pVA.
955. Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease.
作者: Mads Israelsen.;Camila Alvarez-Silva.;Bjørn Stæhr Madsen.;Camilla Dalby Hansen.;Nikolaj Christian Torp.;Stine Johansen.;Johanne Kragh Hansen.;Katrine Prier Lindvig.;Jeanlouis Insonere.;Virginie Riviere.;Helene Bæk Juel.;Asker Brejnrod.;Lars Juhl Jensen.;Maja Thiele.;Benjamin Lelouvier.;Torben Hansen.;Manimozhiyan Arumugam.;Aleksander Krag.; .; .
来源: Gut. 2024年73卷6期1041-1044页 956. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
作者: Loris Riccardo Lopetuso.;Sara Deleu.;Lihi Godny.;Valentina Petito.;Pierluigi Puca.;Federica Facciotti.;Harry Sokol.;Gianluca Ianiro.;Luca Masucci.;Maria Abreu.;Iris Dotan.;Samuel Paul Costello.;Ailsa Hart.;Tariq H Iqbal.;Sudarshan Paramsothy.;Maurizio Sanguinetti.;Silvio Danese.;Herbert Tilg.;Fabio Cominelli.;Theresa T Pizarro.;Alessandro Armuzzi.;Giovanni Cammarota.;Antonio Gasbarrini.;Séverine Vermeire.;Franco Scaldaferri.
来源: Gut. 2023年72卷9期1642-1650页
Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors.
957. Psychological symptoms do not discriminate between reflux phenotypes along the organic-functional refractory GERD spectrum.
作者: Annelies Geeraerts.;Livia Guadagnoli.;Ans Pauwels.;Hannelore Geysen.;Thomas Neyens.;Lukas Van Oudenhove.;Tim Vanuytsel.;Jan Tack.
来源: Gut. 2023年72卷10期1819-1827页
Historically, psychological processes are associated with disorders at the functional end of the gastro-oesophageal reflux disease (GERD) spectrum. However, recent research suggests that psychological symptoms are relevant across the entire GERD spectrum. We aim to investigate whether psychological symptoms are associated with reflux phenotype (True GERD, Borderline GERD, reflux hypersensitivity, functional heartburn) along the GERD spectrum in a cohort of refractory reflux patients.
|